share_log

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

更正:2023年1月19日,Biora Therapeutics收到了纳斯达克通知该公司的信。那个 The Co.”s 先前宣布的投标价格缺陷已得到纠正,该公司已得到纠正符合所有适用的持续上市标准
Benzinga Real-time News ·  2023/01/23 08:57

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

更正:2023年1月19日,Biora Therapeutics收到了纳斯达克通知该公司的信。那个 The Co.”s 先前宣布的投标价格缺陷已得到纠正,该公司已得到纠正符合所有适用的持续上市标准

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发